导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.12% | 2290/4773 |
| 近一周 | -1.92% | 3797/5467 |
| 近一月 | -9.17% | 4160/5421 |
| 近一季 | -15.05% | 4133/5238 |
| 近半年 | -1.13% | 1865/4931 |
| 近一年 | 1.47% | 2250/4400 |
| 近两年 | 59.33% | 1247/2954 |
| 近三年 | 31.63% | 1011/2253 |
| 成立以来 | 59.00% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.39% 2276/4961 |
21.26% 1182/5312 |
- - |
- - |
| 2025 | 26.41% 1632/4813 |
-0.91% 2458/3635 |
-0.49% 2938/4076 |
30.58% 1170/4524 |
-1.83% 3020/4813 |
| 2024 | 12.08% 1272/3463 |
0.37% 991/2808 |
-3.37% 1359/3014 |
19.60% 826/3129 |
-3.37% 2334/3463 |
| 2023 | -14.60% 1611/2656 |
4.37% 971/2280 |
-5.98% 1574/2385 |
-6.84% 1505/2515 |
-6.58% 1834/2655 |
| 2022 | -23.57% 1149/2207 |
-17.90% 1278/1919 |
8.79% 326/2016 |
-15.90% 1366/2113 |
1.75% 1159/2208 |
| 2021 | 1.58% 663/1822 |
-4.24% 851/1255 |
10.76% 439/1330 |
-7.37% 1047/1466 |
3.39% 441/1822 |
| 2020 | 49.86% 175/1250 |
-5.45% 418/1028 |
21.23% 239/1067 |
11.17% 473/1164 |
17.61% 117/1184 |
| 2019 | 53.77% 79/1092 |
36.59% 83/754 |
-2.97% 370/804 |
4.53% 196/850 |
10.99% 85/918 |
| 2018 | -32.20% 522/834 |
- - |
- - |
- - |
-13.63% 544/691 |
| 2017 | 21.10% 169/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.58% 325/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国投瑞银深证100指数 VS. 长安沪深300非周期A(740101) |